Shares in Keros Therapeutics fell sharply Wednesday morning after it said it halted trials of its treatment for pulmonary hypertension after finding adverse health effects in patients trialing the ...

Keros Therapeutics has halted the dosing of its treatment for pulmonary hypertension due to adverse health effects discovered during trials. The clinical-stage biopharmaceutical company said Wednesday ...

A month after halting dosing in two of the three treatment arms of a phase 2 trial of its pulmonary arterial hypertension ...

Taken together with Keros’ recent pivot away from obesity, the termination of its pulmonary arterial hypertension study could ...

Whether you’re a senior in high school or a senior-living resident, you’ve likely heard of Viagra (sildenafil) — the original ...

Retired Worcester firefighter Mark Stomski died on Sunday due to complications from injuries he sustained before his 2008 ...

Background: The use of appetite suppressants in Europe has been associated with the development of primary pulmonary hypertension (PPH). Recently, fenfluramine appetite suppressants became widely ...

The UnitedHealth Group is overcharging patients for necessary life-saving drugs as a result of price gouging that increases ...

Sex-related differences in pulmonary complications were found among men vs women with SSc, specifically in the prevalence of ILD and SAD.

BofA analyst Jason Zemansky lowered the firm’s price target on Keros Therapeutics (KROS) to $32 from $33 and keeps a Buy rating on the shares.

Barclays analyst Matt Miksic maintained a Hold rating on Johnson & Johnson (JNJ – Research Report) today and set a price target of $160.00.

Discover the top stocks for the new year selected by Needham analysts, including ACV Auctions, Alcon, Alegro Microsystems, ...